For many people, the first month mainly helps establish the foundation for steady progress as treatment doses gradually increase
This growing health crisis not only increases the risk of associated comorbidities like type 2 diabetes, cardiovascular diseases, and certain cancers, but also intensifies the urgency for pharmaceutical interventions that aid in sustainable weight loss
In the United States, a lower dose of 60 mg three times daily is approved for over-the-counter use
Subsequently, many different GLP-1R agonists were developed and approved, including : extended release exenatide (exenatide XR), liraglutide, lixisenatide , dulaglutide , and semaglutide (Table 1)
Let us help provide you the predictable results to finally achieve your weight loss goals